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Abstract
This study prospectively compared the preferences for adjuvant systemic therapy of younger and older pa-
tients with early breast cancer. Older patients accepted adjuvant chemotherapy less often than younger pa-
tients. No signiﬁcant difference was found for adjuvant hormonal therapy. The majority of older patients would
still accept therapy. Both age groups required similar beneﬁts in disease-free survival to accept therapy.
Background: It is unknown what minimal beneﬁt in disease-free survival older patients with breast cancer require
from adjuvant systemic therapy, and if this differs from that required by younger patients. We prospectively
examined patients’ preferences for adjuvant chemotherapy (aCT) and adjuvant hormonal therapy (aHT), factors
related to minimally-required beneﬁt, and patients’ self-reported motivations. Patients and Methods: Fifty-two
younger (40-64 years) and 29 older ( 65 years) women with a ﬁrst primary, invasive tumor were interviewed post-
surgery, prior to receiving aCT/aHT recommendation. Results: The proportions of younger versus older participants
who would accept, refuse, or were undecided about therapy were 92% versus 62%, 4% versus 24%, and 4%
versus 14% for aCT, and 92% versus 59%, 8% versus 17%, and 0% versus 24% for aHT. The proportion of older
participants who would refuse rather than accept aCT was larger than that of younger participants (P ¼ .005). No
signiﬁcant difference was found for aHT (P ¼ .12). Younger and older participants’ minimally-required beneﬁt, in
terms of additional 10-year disease-free survival, to accept aCT (median, 5% vs. 4%; P ¼ .13) or aHT (median, 10%
vs. 8%; P ¼ .15) did not differ. Being single/divorced/widowed (odds ratio [OR], 0.16; P ¼ .005), presence of geriatric
condition (inability to perform daily activities, incontinence, severe sensory impairment, depression, polypharmacy,
difﬁculties with walking; OR, 0.27; P ¼ .047), and having a preference to make the treatment decision either alone or
after considering the clinician’s opinion (active role; OR, 0.15; P ¼ .012) were independently related to requiring
larger beneﬁts from aCT. The most frequent motivations for/against therapy included the wish to survive/avoid
recurrence, clinician’s recommendation, side effects, and treatment duration (only aHT). Conclusion:Whereas older
participants were less willing to accept aCT than younger participants, no signiﬁcant difference was found for aHT.
However, a majority of older participants would still accept both therapies. Adjuvant systemic therapy should be
discussed with eligible patients regardless of age.
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Younger and Older Patients’ Preferences for Adjuvant Systemic TreatmentIntroduction consider it worthwhile. Second, to determine which factors are
Breast cancer (BC) is a disease affecting a large proportion of
women over 65 years of age. In Western countries, approximately
40% of new cases occur in older women.1 As the risk of developing
BC increases with age and the general population is aging, the
number of older patients is expected to rise signiﬁcantly.1
In most cases of early stage (I-II) BC, adjuvant systemic therapy is
recommended in addition to primary surgery with or without
postoperative radiotherapy. The addition of adjuvant chemotherapy
(aCT) or adjuvant hormonal therapy (aHT) can lower the risk of
BC relapse and mortality.2 However, these therapies are associated
with short- and long-term side effects, which, in turn, can cause
physical, psychological, and social problems.3 Therefore, the ex-
pected beneﬁts need to be carefully weighed against the side effects.
With regard to older patients, making the decision for or against
systemic therapy is generally difﬁcult. Beneﬁts of adjuvant systemic
therapy in older patients, especially those of aCT, are uncertain
because of small numbers of older women in trials.2,4 Moreover,
high rates of comorbid conditions and polypharmacy in this patient
group pose additional challenges.4 Consequently, treatment de-
cisions in older patients should incorporate their valuation of po-
tential beneﬁts and side effects of treatment strategies.5
So far, data on older patients’ preferences for aCT and aHT are
limited. We performed a systematic review of patients’ preferences,6
and found that most patients judged small to modest survival
beneﬁts sufﬁcient to consider these therapies worthwhile, regardless
of the consequences. A limitation of the reviewed studies was that
the women surveyed had already been treated or had already
received a treatment recommendation, which could have had a
strong inﬂuence on their reported treatment preferences.7 More-
over, most patients were young or middle-aged (mean/median age
of 36-55 years),7-12 and none of the studies on aHT included pa-
tients aged  65 years.8,12
A few studies have retrospectively explored factors that may affect
the decisions about adjuvant systemic treatment of older patients
with BC.13-15 These studies involved only patients aged 65 to 70
years and over, making it difﬁcult to determine whether older pa-
tients place different values on beneﬁts versus side effects of adju-
vant systemic therapy than younger patients. To our knowledge,
solely 1 retrospective study examined age differences in factors
inﬂuencing treatment decisions for aCT and aHT.16 Of the other
existing studies involving patients of all ages, none speciﬁcally
focused on differences in motivations between younger and older
patients.17-19
Given the growing incidence of BC in older women, it will
become increasingly relevant to establish a more complete pic-
ture of treatment preferences in this patient group, and to
determine whether their preferences differ from those of younger
women. A better understanding of older patients’ preferences
and the factors that distinctively affect their preferences will
assist clinicians in determining the set of treatment options
relevant to older patients and in tailoring their information
provision better.
The objectives of this prospective study were three-fold. First, to
examine whether there are differences in the beneﬁt that younger
and older patients minimally require from aCT and aHT toClinical Breast Cancer October 2016related to the minimally-required beneﬁt. Lastly, to examine
whether motivations for and against therapy differ between younger
and older patients.
Patients and Methods
Participants
This study took place at 1 academic and 2 non-academic teaching
hospitals in the Netherlands. Between January 2012 and December
2013, women aged  40 years with a primary invasive tumor
(clinical T1-2) scheduled to undergo surgery with curative intent,
were included. Exclusion criteria were bilateral BC, BRCA 1/2
mutation, history of (non)invasive BC, history of other malignancies
(other than nonmelanoma skin cancer or cervical carcinoma in situ)
within the past 5 years, insufﬁcient knowledge of the Dutch lan-
guage, cognitive/mental problems, inability to participate in a
telephone interview (eg, hearing impairment), and a diagnosis of
metastatic BC after resection. The Medical Ethical Committee of
the Leiden University Medical Center and the institutional review
boards of the participating hospitals approved the study. All par-
ticipants provided informed consent.
Procedure
In a telephone interview, we determined participants’ minimally-
required beneﬁt from aCT and aHT and their motivations for/
against both therapies. Eligible participants were approached
following their diagnosis, and they received an informed consent
form and a self-administered questionnaire on sociodemographic
background. After the presurgical consultation and before surgery,
consenting patients were handed out a questionnaire about their
preferred involvement in decision-making as well as information to
prepare for a telephone interview scheduled after their surgery.
Participants were asked to read the information right before the
interview. Patients usually receive a recommendation for or against
adjuvant systemic therapy based on pathologic ﬁndings following
surgery, during a post-surgical consultation. To rule out that this
recommendation could inﬂuence the participant’s adjuvant treat-
ment preference, the interview was held before that postsurgical
consultation. Three trained interviewers conducted the interviews,
strictly adhering to a script.
Measures
Minimally-Required Beneﬁt and Motivations for/Against Adjuvant
Systemic Therapy. The minimally-required absolute beneﬁt, in terms
of additional 10-year disease-free survival, from aCT and aHT was
assessed using the probability trade-off method.20 As part of this
method, we developed 2 hypothetical scenarios: no aCT versus
aCT, and no aHT versus aHT (see Supplemental Figure 1 in the
online version for details). The scenarios were provided to the
participant and included information about the treatment strategies
and the accompanying health consequences and recurrence risks.
During the interview, we read aloud the information, and asked the
participant to read along. Next, participants were asked to imagine
that their clinician had offered them 2 treatment strategies. We
presented a 10% difference in BC recurrence risk at 10 years be-
tween no aCT (25 out of 100 women with a recurrence) and aCT
Victoria C. Hamelinck et al(15 out of 100 with a recurrence), and asked the participants which
treatment they preferred at this beneﬁt of aCT of 10%. The par-
ticipants were asked to indicate their preference each time in sub-
sequent comparisons, in which the absolute beneﬁt from aCT was
systematically increased or decreased, depending on their answer. If
their initial preference was aCT, we searched for their minimally-
required beneﬁt between the range of 0% (no beneﬁt) and 10%.
If their initial preference was no aCT, we searched for the
minimally-required beneﬁt between the ranges of 11% and 25%
(maximum beneﬁt). Participants could indicate to refuse aCT if
they considered that, for a beneﬁt of 25%, aCT was not worthwhile.
After the aCT scenario, we similarly assessed participants’ preferred
beneﬁt from aHT, except that we presented a 15% difference in 10-
year recurrence risk between no aHT and aHT in the initial
question. At the end of each scenario, we asked participants about
their motivations for their preference.
Participants’ Demographic and Medical Characteristics. The ﬁrst
self-report questionnaire contained questions about sociodemo-
graphic details. Information with regard to type of surgery, co-
morbid conditions, and geriatric health conditions (ie, inability to
carry out daily activities, incontinence, severe sensory impairment,
depression, polypharmacy, difﬁculty with walking21) were extracted
from medical records. Comorbid conditions at the time of diagnosis
were registered according to the 10th revision of the International
Classiﬁcation of Diseases.22
Decisional Role Preference. We assessed participants’ preferred
involvement in decision-making about aCT and aHT using an
adapted version of the Control Preferences Scale.23 Participants
were asked to choose 1 of 5 decisional roles, ranging from (1) the
patient making the decision, (2) the patient making the decision
after considering the clinician’s opinion, (3) the patient making the
decision jointly with the clinician, (4) the clinician making the
decision after considering the patient’s opinion, to (5) the clinician
making the decision.
Statistical Analyses
Participants were categorized into ‘younger’ (40-64 years) and
‘older’ ( 65 years) based on their age at diagnosis. The response
options for decisional role preference were merged into 3 categories:
active (1-2), shared (3), and passive (4-5). Comorbidity was deﬁned
as the sum of any comorbid disease (0, 1, or 2 or more diseases).
Differences in patient characteristics and decisional role preferences
between the groups were examined using the c2 test or the Fisher
exact test, as appropriate.
Participants’ minimally-required beneﬁts to accept aCT and aHT
were categorized into 0%, 1% to 5%, 6% to 10%, 11% to 15%,
16% to 20%, and 21% to 25%. Participants who were undecided
about the minimally-required beneﬁt were excluded from further
analyses. Younger versus older participants’ minimally-required
beneﬁts and acceptance versus refusal of therapy were compared
using the Fisher exact test.
Univariable logistic regression analyses were conducted to
examine the association between minimally-required beneﬁt and
patient characteristics and decisional role preference. The
minimally-required beneﬁt of both aCT and aHT wasdichotomized into 0% to 10% required beneﬁt (‘1’) and 11% to
25% required beneﬁt or refusal of therapy (‘0’). A multivariable
model was built with all signiﬁcant factors (P < .05) in univariable
analysis.
Two researchers independently coded participants’ motivations.
Dissimilarities in coding were resolved through consensus. As this
section was conducted for exploratory purposes, statistical differ-
ences in motivations between the age groups were not tested.
Analyses were conducted using SPSS version 20. A P-value below
.05 was considered statistically signiﬁcant.
Results
Participants
Overall, 100 women with invasive BC were eligible for this study.
Of them, 13 were not interviewed before the postsurgical consul-
tation, and 6 withdrew before the interview. The reasons for
withdrawal were no interest (n ¼ 3), being nervous about getting
the pathology results within the next few days (n ¼ 2), and not
being fully recovered from surgery (n ¼ 1). Eighty-one participants
were included in the analyses. The median time between surgery
and the interview was 6 days (range, 3-12 days), and the telephone
interview lasted on average 30 minutes (range, 10-50 minutes).
The participants’ median age was 61 years (range, 42-86 years).
Fifty-two (64%) participants were aged 40 to 64 years, and 29 (36%)
were aged 65 years (Table 1). Overall, most women were married/
lived together (51 of 81; 63%), had completed an intermediate-level
education (35 of 81; 43%), were employed (38 of 81; 47%), and had
children living at home (49 of 81; 61%). Seventy-two percent (58 of
81) had  1 comorbid condition, and 38% (31 of 81) suffered
from 1 geriatric health condition at diagnosis. Eighty percent (65 of
81) were treated with breast-conserving surgery. Most participants
preferred to share the decision about aCT (42 of 73; 58%) and aHT
(39 of 73; 53%) with the clinician.
Minimally-Required Beneﬁt in 10-Year Disease-Free
Survival From aCT
Some younger (2 of 52; 4%) and older (4 of 29; 14%) par-
ticipants could not decide which beneﬁt they would minimally
require to consider the therapy worthwhile. In the remaining
participants, 92% (48 of 52) of the younger and 62% (18 of 29)
of the older participants, respectively, would accept aCT, and 4%
(2 of 52) of the younger and 24% (7 of 29) of the older partic-
ipants would refuse aCT at the maximum absolute beneﬁt of 25%
(Figure 1A). Older participants refused aCT signiﬁcantly more
often than younger participants (P ¼ .005). Of those who would
accept therapy, the younger participants considered aCT worth-
while at an absolute median beneﬁt of 5% (range, 1%-25%) and
the older participants at an absolute median beneﬁt of 4% (range,
0%-25%). These minimally-required beneﬁts did not signiﬁcantly
differ (P ¼ .13).
Minimally-Required Beneﬁt in 10-Year Disease-Free
Survival From aHT
None of the younger and 24% (7 of 29) of the older participants
were undecided about their minimally-required beneﬁt. In the
remaining group, the majority of younger (48 of 52; 92%) and
older (17 of 29; 59%) participants would accept aHT (Figure 1B).Clinical Breast Cancer October 2016 - 381
Table 1 Characteristics of the Study Population Overall (n [ 81) and by Age Category
Variables
Total
(n [ 81)
40-64 Years
(n [ 52; 64%)
‡65 Years
(n [ 29; 36%)
Pn % n % n %
Patient characteristics
Marital status
Married/living together 51 63 33 63 18 62 .90
Single/divorced/widowed 30 37 19 37 11 38
Educational levela
Low 20 25 13 25 7 24 .19
Intermediate 35 43 19 37 16 55
High 26 32 20 39 6 21
Employment status
Full/part-time 38 47 36 69 2 7 <.001
Housekeeper 9 11 3 6 6 21
Unemployed/long-term sick leave 8 10 8 15 0 0
Retired 26 32 5 10 21 72
Having children
No children 18 22 11 21 7 24 .044
Yes, children not living at home 49 61 28 54 21 72
Yes, children living at home 14 17 13 25 1 3
Number of comorbid conditions
0 23 28 19 37 4 14 .08
1 21 26 13 25 8 28
2 or more 37 46 20 39 17 59
Geriatric health conditionb
No 50 62 35 67 15 52 .17
Yes 31 38 17 33 14 48
Treatment characteristics
Type of surgery
BCS 65 80 43 83 22 76 .46
MAST 16 20 9 17 7 24
Decisional role preferencec
Adjuvant chemotherapyd
Active 19 26 12 26 7 26 .71
Shared 42 58 25 54 17 63
Passive 12 16 9 20 3 11
Adjuvant hormonal therapyd
Active 21 29 14 30 7 26 .42
Shared 39 53 22 48 17 63
Passive 13 18 10 22 3 11
A P-value in bold means a signiﬁcant difference between younger and older participants with respect to that variable.
Abbreviations: BCS ¼ breast-conserving surgery; MAST ¼ mastectomy.
aLevels of education were categorized as low ¼ completed no/primary school; intermediate ¼ completed lower general secondary education/vocational training; or high ¼ completed pre-university
education/high vocational training/university.
bPresence of a geriatric health condition was deﬁned as having one or more of the following characteristics: not able to carry out daily activities, incontinence, severe sensory impairment, depression,
polypharmacy, difﬁculties with walking.
cDecisional role preferences were merged into 3 categories: active (the patient makes the decision alone, the patient makes the decision after considering the clinician’s opinion); shared (the patient
makes the decision together with the clinician); and passive (the clinician makes the decision after considering the patient’s opinion, the clinician makes the decision alone).
dEight participants did not ﬁll out this question before the postoperative consultation.
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382 -Eight percent (4 of 52) of the younger and 17% (5 of 29) of the
older participants would refuse aHT at an absolute beneﬁt of 25%.
Overall, acceptance versus refusal rates did not signiﬁcantly differ
between younger and older participants (P ¼ .12). Of the groupClinical Breast Cancer October 2016accepting therapy, younger and older participants considered it
worthwhile at a median of 10% (range, 1%-25%) and 8% (range,
0%-25%) absolute beneﬁt, respectively. These minimally-required
beneﬁts did not signiﬁcantly differ (P ¼ .15).
Figure 1 The Minimum Absolute Increase in 10-Year Disease-Free Survival that Younger (n [ 52) and Older (n [ 29) Participants
Would Require to Consider Adjuvant Chemotherapy (A) or Hormonal Therapy (B) Worthwhile. In Both Scenarios, the 10-Year
Disease-Free Survival Without Adjuvant Systemic Therapy Was 75%, and the Minimally-Required Beneﬁt to Accept Therapy
Could Range From 0% (No Beneﬁt) to 25% (Maximum Beneﬁt)
Abbreviations: refuse ¼ women who would not accept therapy at any beneﬁt; do not know ¼ women who were undecided about the minimal beneﬁt they would require to consider the therapy
worthwhile; Pdistr ¼ P-value for distribution.
Victoria C. Hamelinck et alFactors Related to Minimally-Required Beneﬁt
Univariable logistic regression analyses showed that participants
who were single/divorced/widowed were signiﬁcantly less likely to
accept aCT (odds ratio [OR], 0.21; 95% conﬁdence interval [CI],
0.08-0.59; P ¼ .003) or aHT (OR, 0.34; 95% CI, 0.13-0.92; P ¼
.033) for 10% beneﬁt or less, compared with participants who were
married/lived together (Table 2). For aHT, there were no other
signiﬁcant factors besides marital status. For aCT, participants with
a geriatric health condition had lower odds of accepting therapy at a
0% to 10% beneﬁt (OR, 0.18; 95% CI, 0.06-0.50; P ¼ .001).
Furthermore, participants who preferred an active decisional role
were less likely to accept aCT at a 0% to 10% beneﬁt thanparticipants who preferred a shared decisional role (OR, 0.25; 95%
CI, 0.08-0.81; P ¼ .021).
Factors included in the multivariable model for aCT were marital
status, geriatric health condition, and decisional role preference. The
participants who were single/divorced/widowed had an OR of 0.16
(95% CI, 0.04-0.57; P ¼ .005) for accepting aCT at a 0% to 10%
beneﬁt, compared with participants who were married/living
together. Having a geriatric condition was related to requiring larger
beneﬁts to accept aCT (OR, 0.27; 95% CI, 0.07-0.98; P ¼ .047).
Having an active decisional role preference was related to requiring
larger beneﬁts compared with having a shared decisional role pref-
erence (OR, 0.15; 95% CI, 0.04-0.67; P ¼ .012).Clinical Breast Cancer October 2016 - 383
Table 2 Univariable Logistic Regression Analysis Between Patient Characteristics, Type of Surgery, and Decisional Role Preferences
and Accepting aCT (n [ 75)a and aHT (n [ 74)a at a 0% to 10% Beneﬁt
Participants
who Would
Accept aCT
at a 0%-10%
Beneﬁt (%) ORb 95% CI P
Participants who
Would Accept
aHT at a 0%-10%
Beneﬁt (%) ORb 95% CI P
Patient characteristics
Age in years
40-49 78 1 (ref) 78 1 (ref)
50-59 88 2.00 (0.28-14.53) .49 44 0.22 (0.04-1.30) .10
60-69 59 0.42 (0.07-2.39) .33 63 0.49 (0.08-2.81) .42
70 40 0.19 (0.03-1.25) .08 46 0.25 (0.04-1.66) .15
Marital status
Married/living together 79 1 (ref) 65 1 (ref)
Single/divorced/widowed 44 0.21 (0.08-0.59) .003 39 0.34 (0.13-0.92) .033
Educational levelc
Low 79 1 (ref) 50 1 (ref)
Intermediate 64 0.47 (0.13-1.73) .26 59 1.46 (0.46-4.67) .52
High 61 0.42 (0.10-1.66) .21 54 1.18 (0.35-4.02) .79
Employment status
Full/part-time 75 1 (ref) 55 1 (ref)
Housekeeper 75 1.00 (0.17-5.87) 1.00 50 0.81 (0.18-3.73) .79
Unemployed/long-term sick leave 50 0.33 (0.07-1.62) .17 50 0.81 (0.18-3.73) .79
Retired 57 0.43 (0.14-1.33) .14 60 1.21 (0.40-3.65) .73
Having children
No 63 1 (ref) 43 1 (ref)
Yes, children not living at home 65 1.13 (0.35-3.66) .85 57 1.73 (0.52-5.80) .37
Yes, children living at home 77 2.00 (0.39-10.31) .41 64 2.40 (0.52-10.99) .26
Number of comorbid conditions
0 81 1 (ref) 64 1 (ref)
1 65 0.44 (0.11-1.82) .26 58 0.79 (0.22-2.77) .71
2 or more 59 0.34 (0.09-1.22) .10 49 0.54 (0.18-1.62) .27
Geriatric health conditiond
No 81 1 (ref) 64 1 (ref)
Yes 43 0.18 (0.06-0.50) .001 41 0.39 (0.15-1.03) .06
Treatment characteristics
Type of surgery
BCS 68 1 (ref) 51 1 (ref)
MAST 60 0.70 (0.22-2.23) .54 73 2.66 (0.76-9.31) .13
Decisional role preferencee,f
Shared 72 1 (ref) 56 1 (ref)
Active 39 0.25 (0.08-0.81) .021 40 0.53 (0.18-1.62) .27
Passive 80 1.57 (0.29-8.60) .60 67 1.60 (0.41-6.29) .50
A P-value in bold means a signiﬁcant difference between that group and the reference group.
Abbreviations: aCT¼ adjuvant chemotherapy; aHT¼ adjuvant hormonal therapy; BCS ¼ breast-conserving surgery; CI ¼ conﬁdence interval; MAST ¼ mastectomy; OR ¼ odds ratio; ref ¼ reference.
aParticipants who could not decide upon their minimally-required beneﬁt were excluded (aCT, n ¼ 6; aHT, n ¼ 7).
bAn OR over 1 indicates a greater likelihood to accept therapy at a 0% to 10% beneﬁt, an OR below 1 indicates a lower likelihood to accept therapy at a 0% to 10% beneﬁt (and a greater likelihood to
require a > 10% beneﬁt).
cLevels of education were categorized as low ¼ completed no/primary school; intermediate ¼ completed lower general secondary education/vocational training; or high ¼ completed pre-university
education/high vocational training/university.
dPresence of a geriatric health condition was deﬁned as having one or more of the following characteristics: not able to carry out daily activities, incontinence, severe sensory impairment, depression,
polypharmacy, difﬁculties with walking.
eDecisional role preferences were merged into 3 categories: active (the patient makes the decision alone, the patient makes the decision after considering the clinician’s opinion); shared (the patient
makes the decision together with the clinician); and passive (the clinician makes the decision after considering the patient’s opinion, the clinician makes the decision alone).
fEight respondents did not ﬁll out the questions about aCT and aHT before the postoperative consultation and were excluded from this analysis.
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Victoria C. Hamelinck et alMotivations in Favor of or Against Adjuvant Systemic
Therapy
Both younger and older participants frequently reported that the
wish to survive/avoid recurrence and the treatment recommenda-
tion of their clinician were motivations in favor of aCT (Table 3). In
the case of aHT, younger participants frequently cited the clinician’s
recommendation and wanting to survive/avoid recurrence as argu-
ments for the therapy. For older participants, the clinician’s
recommendation was the predominant argument.
For both younger and older participants, the most often reported
argument against aCT was concern about potential side effects.
Older participants also commonly reported that the wish to main-
tain their current quality of life and independence, the negative
treatment experience of others, the beneﬁts not outweighing side
effects, and their old age were arguments against aCT. Regarding
aHT, both age groups frequently noted that side effects and the long
duration of treatment were arguments against the therapy.Discussion
This prospective study compared the minimal beneﬁt in 10-year
disease-free survival that younger and older patients with early BC
would require to consider aCT and aHT worthwhile. Additionally,
we assessed which factors were related to the minimally-required
beneﬁt, and explored younger and older patients’ motivations for
and against these therapies. To our knowledge, this is the ﬁrst study
that examined preferences for aCT and aHT in older patients24 and
before patients received a recommendation for or against adjuvant
systemic therapy, thereby minimizing the biasing inﬂuence of
cognitive dissonance reduction. This cognitive mechanism of
adaptation leads individuals to reduce inconsistencies between
previous decisions (such as treatment decisions) and current beliefs.
Thus, patients will tend to justify earlier decisions about how they
will be treated in such ways that their current preferences are in
accordance with that decision.7 In the present sample, participants
did not know which treatment was indicated, and no treatment
decision was yet made. We are aware that participants may already
have had a treatment preference, based on clinical information they
received after diagnosis (eg, having a very large tumor), experiences
from signiﬁcant others, or from information found on the Internet
or elsewhere. This is true also in daily practice.
Our results reveal that older participants would more often refuse
aCT than younger participants, but no signiﬁcant difference was
found regarding aHT. However, the proportion of older partici-
pants willing to accept systemic therapy was large (3 out of 5
women, for both aCT and aHT), and for these older women, the
minimally-required beneﬁt did not differ from that of younger
women. The latter ﬁnding is in line with other studies on aCT that
found no association between age and minimally-required beneﬁt,
in terms of overall9-11 or disease-free survival,7 but not with other
studies demonstrating in contrast that higher age was related to
higher minimally-required beneﬁt from aCT25,26 or aHT.26 How-
ever, our study as well as earlier studies7,9-11 showing no such as-
sociation differ from the latter two25,26 regarding design and
population in the following way. First, in the 2 latter studies, it was
unclear whether participants could refuse therapy. Second, the latter
studies also involved more advanced BC stages, which could lead todifferent treatment preferences. Based on our results, it appears that,
for early-stage BC, age is not a factor in determining the minimally-
required beneﬁt, and that the majority of patients are willing to
consider adjuvant systemic therapy. It is important for clinicians to
be aware of these preferences.
Another ﬁnding was that some participants, predominantly older
participants, were undecided about the minimal beneﬁt they would
require to consider adjuvant systemic therapy worthwhile. Partici-
pants primarily reported they would rely on the treatment advice of
their clinician. It is important that clinicians themselves are aware of
this ﬁnding, and they should try to ensure that information pro-
vision is clear and tailored to the needs of the patient. Additionally,
patients should be made aware that they should voice their prefer-
ences and concerns.
Another ﬁnding was that being single, divorced, or widowed,
having a geriatric health condition, and having a preference for an
active decisional role predicted patients’ preference for aCT.
Women who were single/divorced/widowed had a 5 times higher
odds of requiring a large beneﬁt than women who were married/
living together. This may be explained by either not having a
partner for whom to consider a treatment worthwhile (“to live for”),
or by lack of support from a partner during treatment. If a patient
has 1 or more geriatric health conditions, she might be more likely
to think that she might not cope with the side effects of adjuvant
systemic therapy, and thus her minimally-required beneﬁt should be
higher to make it worthwhile. The association with role preference
may be explained by 2 mechanisms with a different causal direction.
On the one hand, patients who do not want aCT may want to be
actively involved to ensure that no overtreatment occurs. That is,
patients’ existing treatment preference may determine their role
preference. On the other hand, it has been found that patients who
are more active, following the use of a decision aid, tend to choose
more conservative treatment,27 implying that decisional role may
explain treatment preference.
As expected, the predominant motivation in favor of aCT was to
survive/avoid recurrence, irrespective of age. Nevertheless, older
participants seemed to value the clinician’s recommendation more
compared with younger participants. These 2 factors have often
been noted in previous studies concerning older patients’ decision-
making about aCT13,14 and about treatment for BC in general.15,28
Further, our study indicated that motivations against aCT largely
differed between younger and older participants. Both groups
frequently reported concern about side effects as a motivation.
Additionally, older participants reported the wish to maintain their
current quality of life and independence and the belief that beneﬁts
do not outweigh side effects as concerns about aCT. As these
concerns are speciﬁc to older patients, more focus should be placed
on quality of life and independence when discussing treatment
consequences, and sufﬁcient information should be provided to help
develop realistic expectations on side effects of aCT. This will better
support older patients in developing an informed treatment pref-
erence. Interestingly, although age was not a factor in determining
the minimally-required beneﬁt to accept therapy, it was an impor-
tant argument for women in deciding for or against adjuvant sys-
temic therapy. The most striking observation was that older
participants more frequently stated that their old age was an argu-
ment against aCT.Clinical Breast Cancer October 2016 - 385
Table 3 Arguments in Favor of and Against aCT (n [ 75)a and aHT (n [ 74)a According to Age Categoryb
aCT aHT
40-64 Years
(n [ 50)
%
‡65 Years
(n [ 25)
%
40-64 Years
(n [ 52)
%
‡65 Years
(n [ 22)
%
Arguments in favor of systemic therapy
Wish to survive/avoid recurrence/do everything possible to ﬁght the cancer 40 28 25 14
Clinician’s recommendation for treatment 24 36 25 36
Downplays side effects/not everybody will have side effects 14 16 13 18
Positive treatment experience of others 12 4 6 0
Age (“I am too young”) 12 4 6 0
Potential beneﬁts outweigh potential side effects 12 8 8 18
Someone (eg, partner, [grand] children) to live for 6 4 6 5
Reduce possible (future) regret 6 4 4 5
Trust in (effectiveness) of treatment 2 4 2 5
Preference based on feeling (not further speciﬁed) 2 0 4 0
Trust in the capability of my body to deal with the drug 0 4 0 0
Speciﬁc for aCT
Short duration of treatment 2 0 e e
Speciﬁc for aHT
Able to discontinue therapy in case of many/severe side effects e e 8 5
Is experiencing/has experienced little/no menopausal complaints e e 6 18
Not having to go to hospital to undergo treatment e e 2 0
Medication/life style changes possible to lessen the severity of side effects e e 2 0
Taking a daily pill is not a burden e e 2 9
Arguments against systemic therapy
Concerns about short- and/or long-term side effects 50 40 42 36
Maintain quality of life/independence/continue work 12 24 10 18
Negative treatment experience of others 12 20 8 0
Health status/condition 12 12 8 14
Potential beneﬁts do not outweigh potential side effects 8 24 0 5
Undergoing adjuvant systemic therapy does not guarantee no recurrence 6 8 0 5
Relies on regular check-ups/option of new therapy in case of recurrence 4 0 2 0
Hopes to be cured without adjuvant systemic therapy 2 0 2 0
Age (“I am too old”) 2 24 2 9
Lack of social support 2 8 2 5
Long duration of treatment 2 0 40 23
No or little trust in (effectiveness) of treatment 0 0 0 5
Speciﬁc for aCT
Frequent hospital visits for chemotherapy are a burden 2 4 e e
Fear of needles 2 0 e e
Speciﬁc for aHT
Is experiencing/has experienced many/severe menopausal complaints e e 6 0
Taking a daily pill is a burden e e 2 0
Negative experience with hormones e e 2 0
“e” Indicates that the argument is not applicable to the therapy.
Abbreviations: aCT ¼ adjuvant chemotherapy; aHT ¼ adjuvant hormonal therapy.
aParticipants who could not decide upon their minimally-required beneﬁt were excluded (aCT, n ¼ 6; aHT, n ¼ 7).
bParticipants could indicate more than 1 argument.
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except that the wish to survive/avoid recurrence was less frequently
reported. An explanation may be that participants generally know lessClinical Breast Cancer October 2016about this treatment compared with aCT, and thus possibly doubt or
underestimate the effectiveness of aHT. The wish to survive/avoid
recurrence and the clinician’s recommendation were valued equally in
Victoria C. Hamelinck et alyounger participants. This was not found for older participants who
considered the clinician’s recommendation most important. With
regard to arguments against aHT, no overt differences were found in
the predominant motivations between the age groups.
Some limitations of this study need to be noted. Participants were
approached before they actually faced a decision. Although they
probably would be confronted with this decision, the preference
they reported here might still differ from their preference once they
had received a recommendation. Further, fewer older participants
than anticipated could be included in the study. This was owing to
the fact that primarily older participants were excluded based on the
exclusion criterion of having a previous malignancy (11 older
compared with 2 younger women). Nevertheless, comparison of our
older participants with older patients with early-stage invasive BC
enrolled in a population-based cohort study in the Netherlands29
showed that our sample compared favorably with the average
older woman with BC with regard to median age and presence of
comorbid and geriatric conditions. Finally, because our sample was
small, further investigation about younger and older participants’
preferences for aHT in a larger sample is required.Conclusion
This prospective study revealed that, whereas older participants
were less willing to undergo aCT than younger participants, no sig-
niﬁcant difference was found for aHT. Still, a majority of older par-
ticipants would accept both therapies, and these women required
similar beneﬁts in 10-year disease-free survival as younger women.
The option of adjuvant systemic therapy should therefore be discussed
with eligible patients regardless of age. Younger and older participants’
motivations for and against therapy generally did not differ, except
that, contrary to younger participants, older participants reported
multiple motivations against aCT, which included fear of treatment-
related toxicity, the wish to maintain current quality of life and in-
dependence, the negative treatment experience of others, beneﬁts not
outweighing side effects, and old age. Clinicians should explore what
matters most to the patient, elicit their preference, and incorporate
these evaluations in their treatment recommendation.
Clinical Practice Points
 To date, little is known about older patients’ preferences for aCT
and aHT. Previous studies have mainly focused on young or
middle-aged patients. The scarcity of evidence on older patients’
treatment preferences indicates that clinicians have no clear
guidance about what older patients generally desire. Several
studies demonstrated that patient age often inﬂuences clinicians’
advice about adjuvant systemic therapy.30,31 This ageism may
partially explain why older patients more often receive subopti-
mal therapy than younger patients, which might then be asso-
ciated with lower survival rates.32
 Our prospective study has generated new knowledge that can be
of help when making adjuvant treatment decisions with older
patients. We found that the proportion of older women that
would accept adjuvant systemic therapy was large, and for these
women the minimally-required beneﬁt for aCT and aHT did not
differ from that of younger women. Also, we found a largevariation in preferences within the older group, suggesting that
each individual older patient may value the beneﬁts and side
effects of treatment strategies differently.
 It is necessary to involve older patients in the decision-making
process. This requires patients to be made aware that adjuvant
systemic therapy is an option. Next, the beneﬁts and side effects
involved, including the associated uncertainty given the in-
dividual’s biological age, should be discussed. It is essential to
explicitly explore the patient’s consideration as to whether the
expected beneﬁt is worth the side effects.33Acknowledgments
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